Shahriar Matin
Chief Operating Officer
Pharmaceutical
Avatcha, Production Firm, Limited Liability Company
Russian Federation
Biography
Shar Matin has served as Chief Operating Officer of Spectranetics since 2014. Following the closing of AngioScore Inc. in 2014 and Stellarex™ in 2015, Matin became the President of the AngioScore subsidiary and leads Spectranetics’ drug-coated balloon programs. At Spectranetics, Matin started his career as Managing Director of Europe, Russia and the Middle East in 2007. He was promoted to Vice President and Managing Director, International, in 2008. In 2010, He became Senior Vice President of Operations, Product Development and International, and in 2012, he became Senior Vice President of Operations, Business Development and International. Before joining Spectranetics, Matin was the Business Unit Director for Boston Scientific’s cardiac rhythm management operations in China and served in several commercial and engineering roles at Guidant Corporation. Mr. Matin serves on the board of directors of the Fitzsimons Redevelopment Authority in Aurora, Colorado Mr. Matin earned a BS in Mechanical Engineering from the University of California, Berkeley, with honors, and an MBA from Harvard Business School.
Research Interest
Pharmaceutical Sciences
